Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
Want to see KLRS full AI Analyst Report?
Total Valuation
Kalaris Therapeutics has a market cap or net worth of $105.43M. The enterprise value is $57.32M.
Market Cap$105.43M
Enterprise Value$57.32M
Share Statistics
Kalaris Therapeutics has 23,792,278 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,792,278
Owned by Insiders54.44%
Owned by Institutions4.37%
Financial Efficiency
Kalaris Therapeutics’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -41.08%.
Return on Equity (ROE)-0.55
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-41.08%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee0.00
Profits Per Employee-3.10M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kalaris Therapeutics is ―. Kalaris Therapeutics’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio1.63
Price to Fair Value1.63
Price to FCF-2.98
Price to Operating Cash Flow-2.34
PEG Ratio0.04
Income Statement
In the last 12 months, Kalaris Therapeutics had revenue of 0.00 and earned -43.44M in profits. Earnings per share was -2.85.
Revenue0.00
Gross Profit-13.00K
Operating Income-46.15M
Pretax Income-43.44M
Net Income-43.44M
EBITDA-46.14M
Earnings Per Share (EPS)-2.85
Cash Flow
In the last 12 months, operating cash flow was -48.88M and capital expenditures -200.00K, giving a free cash flow of -49.09M billion.
Operating Cash Flow-48.88M
Free Cash Flow-49.09M
Free Cash Flow per Share-2.06
Dividends & Yields
Kalaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.83
52-Week Price Change62.08%
50-Day Moving Average6.10
200-Day Moving Average6.49
Relative Strength Index (RSI)37.05
Average Volume (3m)136.22K
Important Dates
Kalaris Therapeutics upcoming earnings date is Aug 19, 2026, Before Open (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 19, 2026
Ex-Dividend Date―
Financial Position
Kalaris Therapeutics as a current ratio of 12.23, with Debt / Equity ratio of 2.06%
Current Ratio12.23
Quick Ratio12.23
Debt to Market Cap<0.01
Net Debt to EBITDA2.09
Interest Coverage Ratio-31.98
Taxes
In the past 12 months, Kalaris Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kalaris Therapeutics EV to EBITDA ratio is -0.70, with an EV/FCF ratio of -0.75.
EV to Sales0.00
EV to EBITDA-0.70
EV to Free Cash Flow-0.75
EV to Operating Cash Flow-0.75
Balance Sheet
Kalaris Therapeutics has $97.22M in cash and marketable securities with $1.41M in debt, giving a net cash position of $95.81M billion.
Cash & Marketable Securities$97.22M
Total Debt$1.41M
Net Cash$95.81M
Net Cash Per Share$4.03
Tangible Book Value Per Share$5.16
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kalaris Therapeutics is $15.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.75
Price Target Upside149.21% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast73.91%